Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events.

ABSTRACT:

Aims

Immune-related adverse events (irAEs) are common side effects of immune checkpoint inhibitor (ICI) cancer therapy, affecting approximately half of ICI-treated patients. irAEs may be severe and result in hospitalization. This study examined the risk factors and outcomes of irAE-related hospitalization.

Methods

We conducted a retrospective study including 202 metastatic cancer patients treated with ICIs at Kuopio University Hospital, Finland, in 2015-2022.

Results

IrAEs occurred in 57.4% of the patients. About 26.0% of them required inpatient treatment. Hospitalization was associated with severe (grades III - IV) toxicities and need for systemic corticosteroids. Median overall survival (mOS) for hospitalized patients was 12.9 months and for outpatients with irAEs 2

SUBMITTER: Nurmela V 

PROVIDER: S-EPMC12045564 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature